Summary of COVID-19 amantadine studies
Hide extended summaries
RCT 99 patients showing higher complete recovery rates with amantadine, but no significant difference in progression. Authors suggest amantadine's central nervous system effects may have contributed to faster recovery by reducing neuropsychiatric symptoms.
Sep 2023, European J. Neurology, https://onlinelibrary.wiley.com/doi/10.1111/ene.16045, https://c19p.org/rejdak
RCT 186 hospitalized COVID-19 patients showing no significant differences with oral amantadine compared to placebo.
Jun 2023, Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S0954611123000860, https://c19p.org/barczyk
RCT 242 non-hospitalized COVID-19 patients showing no benefit of amantadine for disease progression.
Oct 2023, Clinical Microbiology and Infection, https://www.sciencedirect.com/science/article/pii/S1198743X23003014, https://c19p.org/weis
1. Rejdak et al., Amantadine in unvaccinated patients with early, mild to moderate COVID‐19: A randomized, placebo‐controlled, double‐blind trial
99 patient amantadine late treatment RCT: 39% improved recovery (p=0.03) and 89% lower progression (p=0.12).RCT 99 patients showing higher complete recovery rates with amantadine, but no significant difference in progression. Authors suggest amantadine's central nervous system effects may have contributed to faster recovery by reducing neuropsychiatric symptoms.
Sep 2023, European J. Neurology, https://onlinelibrary.wiley.com/doi/10.1111/ene.16045, https://c19p.org/rejdak
2. Barczyk et al., Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study
186 patient amantadine late treatment RCT: 13% higher mortality (p=0.83) and 18% lower ICU admission (p=0.75).RCT 186 hospitalized COVID-19 patients showing no significant differences with oral amantadine compared to placebo.
Jun 2023, Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S0954611123000860, https://c19p.org/barczyk
3. Weis et al., Amantadine for COVID-19 treatment (ACT) study: a randomized, double-blinded, placebo-controlled clinical trial
242 patient amantadine late treatment RCT: 48% worse recovery (p=0.1).RCT 242 non-hospitalized COVID-19 patients showing no benefit of amantadine for disease progression.
Oct 2023, Clinical Microbiology and Infection, https://www.sciencedirect.com/science/article/pii/S1198743X23003014, https://c19p.org/weis
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.